Nissan stuns vehicle buyers with new ultra-affordable electric vehicle — and it's far from bare-bones
Nissan is stepping up its electric vehicle game by cutting back the price of its newest EV. According to Electrek, the new Nissan N7 sedan, which was recently unveiled at the Shanghai International Automobile Industry Exhibition, starts at only $16,500.
This may be Nissan's attempt at competing with Chinese EV giant BYD, which recently released the Qin L for $16,500.
Despite the low price, the N7 isn't some bare-bones EV without any flashy smart tech. It comes with high-speed navigation, city memory navigation, as well as intelligent parking, all of which can be controlled using the 15.6-inch infotainment monitor. It also comes with AI voice interaction.
The N7 doesn't sacrifice much on range either. It comes in five different models, which can trek from 316 miles on a single charge to 388.
One of the reasons Nissan is able to sell the N7 for so cheap is because it has a lithium iron phosphate battery pack rather than a lithium-ion battery made using nickel, manganese, and cobalt like a lot of EVs. LFP batteries are significantly cheaper to manufacture. Volkswagen used the same strategy in manufacturing its new affordable EV, the ID.2.
Unfortunately, none of the affordable EVs mentioned here will be hitting the streets in the United States any time soon, though that could always change with enough consumer demand. For now, the N7 and Qin L are focused on the Chinese market, and the ID.2 is targeting the European market.
EVs already have well-known money-saving benefits over gas-powered vehicles in that they don't require as much maintenance and the driver doesn't need to worry about fluctuating gas prices. That's on top of the fact that EVs don't produce planet-warming pollution that contributes to extreme weather events.
But for some, EVs might not have been an option because they're generally a little more expensive. Cheaper EVs such as the N7 could convince consumers to make their next car an EV.
Home solar can increase the savings from owning an EV by cutting charging costs. Charging at home using solar power is cheaper than using public charging stations or energy from the grid. EnergySage provides homeowners with a free service that helps them compare quotes from vetted solar installers as well as any rebates or tax incentives for going solar. Additionally, Palmetto has a solar leasing program called LightReach, which helps you install panels on your home for no money down and still lock in low energy rates.
If you were going to purchase an EV, which of these factors would be most important to you?
Cost
Battery range
Power and speed
The way it looks
Click your choice to see results and speak your mind.
Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
China Boosts Credit with $204B Bond Push--But Borrowing Stays Muted
China's credit growth picked up in Maybut the momentum came from Beijing, not the private sector. The People's Bank of China reported nearly 1.5 trillion yuan ($204 billion) in government bonds were sold last month, roughly 20% higher than a year ago. That marks the third time in 2025 bond sales have topped 1 trillion yuan in a single month. The surge helped lift total aggregate financing to 2.29 trillion yuan, an increase from 2 trillion yuan in May 2024. On the ground, though, the appetite for new borrowing looks subdued. Households took out just 54 billion yuan in new loans last month, bringing the year-to-date total to 572 billion yuanthe lowest since at least 2009. New loans from financial institutions also fell, landing at 620 billion yuan, well below last year's 945 billion yuan for the same period. This comes even after the PBOC announced sweeping monetary easing in early May, including across-the-board rate cuts and liquidity moves that could inject 2.1 trillion yuan into the economy. According to Bloomberg Economics' Eric Zhu, May's numbers suggest the government is delivering on its stimulus plans, but the response from households and businesses remains cautious. For global investors watching China's recovery story, the next leg of growth may depend on whether demand strengthens beyond public-sector activity. Companies with strong exposure to the Chinese consumer, including Tesla (NASDAQ:TSLA), could be watching for early signs of a turn in private-sector sentiment. This article first appeared on GuruFocus.
Yahoo
37 minutes ago
- Yahoo
AstraZeneca taps Chinese biotech in $5.2bn chronic disease research deal
AstraZeneca has joined the long list of big pharma companies enlisting the services of Chinese biotechs, signing a deal worth up to $5.2bn with CSPC Pharmaceuticals to research chronic disease drug candidates. Under the deal, AstraZeneca will pay an upfront fee of $110m, along with milestone payments of $1.62bn. CSPC are also in line to receive $3.6bn in sales milestone payments. AstraZeneca and CSPC will discover and develop pre-clinical candidates for multiple targets, which, according to the companies, will have the 'potential to treat diseases across chronic indications, including a pre-clinical small molecule oral therapy for immunological diseases'. CSPC will use its AI-powered drug discovery platform, which uses the technology to analyse the binding patterns of target proteins with existing compound molecules. The AI models work out targeted optimisation, advancing small molecules with the best developability. For any candidates identified via the research partnership, AstraZeneca will have the right to exercise options for exclusive licences to develop and commercialise candidates worldwide. AstraZeneca's executive vice president and biopharmaceuticals R&D head Sharon Barr said: 'This strategic research collaboration underscores our commitment to innovation to tackle chronic diseases, which impact over two billion people globally. 'Forming strong collaborations allows us to leverage our complementary scientific expertise to support the rapid discovery of high-quality novel therapeutic molecules to deliver the next-generation medicines.' The partnership marks the second time this year AstraZeneca has invested resources in China. In March 2025, the drugmaker revealed plans to infuse $2.5bn over the next five years in Beijing to establish an R&D hub. China is enjoying a fruitful alliance with Western big pharma companies, despite a frosty relationship with US President Trump's administration, mainly due to the BIOSECURE ACT, which is admittedly now in legislative limbo. Licensing deals between US and Chinese biopharma companies hit record highs last year, up 280% from 2020, according to analysis by GlobalData. Across big pharma, transactions rose 66% from $16.6bn in 2023 to $41.5bn in 2024, demonstrating that China is still the go-to place to discover pipeline candidates. For deals specific to US companies, the analysis found that total deal value rose from $15.7bn in 2023 to $21.3bn in 2024. GlobalData is the parent company of Pharmaceutical Technology. "AstraZeneca taps Chinese biotech in $5.2bn chronic disease research deal" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
1.1 million Anker power banks recalled over fire risks
June 13 (UPI) -- Anker Innovations Technology Co. is recalling more than 1.1 million of its power banks over fire concerns related to the products' lithium-ion batteries. The publicly-traded Chinese company is recalling 1.158 million of the A1263 models of its Anker PowerCore 10000 power banks, according to a recall notice issued by the U.S. Consumer Product Safety Commission. The power bank batteries "can overheat, posing fire and burn hazards to consumers," the recall notice states. Affected units were produced in China and have the company's name, Anker, engraved on the front of the power banks. They were sold in the United States through Anker, Amazon, Newegg and Ebay between June of 2016 and December 2022. To date, the company has received 19 reports of fires and explosions related to the devices, which retail for about $27. The incidents include two reports of minor burns and 11 involving property damage causing a collective $60,700. "Consumers should immediately stop using the recalled power banks and contact Anker Innovations for instructions on receiving a free replacement power bank," Anker said in the recall notice. Customers can get a replacement by sending the company a photo of their recalled unit. The photo must display the model and serial number as well as the date the photo was taken among other parameters. Owners will also need to confirm they have properly disposed of the faulty unit. "Do not throw this recalled lithium-ion battery or device in the trash, in the general recycling stream,, or in used battery recycling boxes found at various retail and home improvement stores. Recalled lithium-ion batteries must be disposed of differently than other batteries, because they present a greater risk of fire," the company said in the recall notice. "Your municipal household hazardous waste collection center may accept this recalled lithium-ion battery or device for disposal. Before taking your battery or device to a HHW collection center, contact it ahead of time and ask whether it accepts recalled lithium-ion batteries. If it does not, contact your municipality for further guidance." Anker was founded in September of 2011 and is headquartered in the city of Changsha in China's Hunan province.
